Ms. Kalin has been a director of the Company since August 2022. Ms. Kalin currently serves as a non-executive director on the boards of Genfit S.A. (NASDAQ: GNFT), a French, public biopharmaceutical company, where she serves on the Strategy and Alliances Committee, and two private companies, Brown Advisory LLC, an independent investment and strategic advisory firm (Audit & Finance Committees), and FemHealth Ventures, a venture capital firm that seeks to invest in women’s health. She was a member of the board of directors of Athersys (NASDAQ: ATHX), a biotech focused on regenerative medicine from 2020 to 2022 (Audit and Compensation Committees) and Clinical Genomics, a private, biotech company dedicated to improving patient outcomes through early detection of colorectal cancer (Audit and Financial Risk Committee) from 2018 to 2021. She currently serves as a trustee for a not-for-profit organization, the Summit Foundation, a 501(c)(3) community foundation that fosters local philanthropy. Ms. Kalin has more than 25 years of experience in healthcare and professional services, most recently at Celgene, where she led Corporate Strategy from 2012 to 2017, and at Johnson & Johnson, where she held executive leadership roles in marketing, sales and new business development from 2002 to 2011. Prior to that, Ms. Kalin was a partner in the global healthcare practice at McKinsey & Co., from 1990 to 2002. Her healthcare industry experience spans pharmaceuticals, diagnostics, medical devices, and digital health. Earlier in her career, she served as a Manager in Corporate Finance at Nomura International in the U.K. and Japan from 1984 to 1988. She has a B.A. from Durham University, U.K. and an M.B.A. from Harvard Business School.
What is Katherine Bach Kalin's net worth?
The estimated net worth of Katherine Bach Kalin is at least $607.61 thousand as of November 19th, 2025. Kalin owns 104,400 shares of SELLAS Life Sciences Group stock worth more than $607,608 as of March 11th. This net worth approximation does not reflect any other investments that Kalin may own. Learn More about Katherine Bach Kalin's net worth.
How do I contact Katherine Bach Kalin?
Has Katherine Bach Kalin been buying or selling shares of SELLAS Life Sciences Group?
Katherine Bach Kalin has not been actively trading shares of SELLAS Life Sciences Group during the last ninety days. Most recently, on Wednesday, November 19th, Katherine Bach Kalin bought 63,400 shares of SELLAS Life Sciences Group stock. The stock was acquired at an average cost of $1.59 per share, with a total value of $100,806.00. Following the completion of the transaction, the director now directly owns 104,400 shares of the company's stock, valued at $165,996. Learn More on Katherine Bach Kalin's trading history.
Who are SELLAS Life Sciences Group's active insiders?
Are insiders buying or selling shares of SELLAS Life Sciences Group?
During the last twelve months, SELLAS Life Sciences Group insiders bought shares 3 times. They purchased a total of 93,400 shares worth more than $149,406.00. The most recent insider tranaction occured on November, 19th when Director Katherine Bach Kalin bought 63,400 shares worth more than $100,806.00. Insiders at SELLAS Life Sciences Group own 1.2% of the company.
Learn More about insider trades at SELLAS Life Sciences Group. Information on this page was last updated on 11/19/2025.